Kento Tomohisa, Toma Abe, Ken Sota, Akiho Kato, Shigeo Sakurako, Tokuda Kaoru and Taka Yoshizawa
Introduction: The effectiveness and safety of romiplostim were evaluated by immune thrombocytopenia (ITP) phase (newly diagnosed/ persistent/chronic) at romiplostim initiation.
Methods: This is a post hoc analysis of a prospective, Japanese, multicentre, observational study in adults with ITP who received ≥ 1 dose of romiplostim. Follow-up data were collected for ≤ 2 years. Outcomes included overall platelet response (≥ 1 platelet count ≥ 50 × 109/L at 2–24 weeks after romiplostim initiation) or durable platelet response (≥ 75% of measurements ≥ 50 × 109/L at 14–24 weeks) and adverse drug reactions (ADRs), evaluated by ITP phase.
Results: Data from 96 patients were analysed (newly diagnosed, n =18; persistent, n=25; chronic, n=53). During the 2- to 24-week follow-up, overall platelet response was achieved in 100% (95% confidence interval: 81.5–100), 100% (86.3–100), and 96.2% (87.0–99.5) of patients with newly diagnosed, persistent, or chronic ITP, respectively, and platelet responses were durable in 88.2% (63.6–98.5), 65.0% (40.8–84.6), and 69.4% (54.6–81.7) of patients. During the 2-year follow-up, ADRs occurred in 24.0–35.8% of patients across phases. Two patients with chronic ITP experienced bone marrow ADRs; no thrombotic ADRs occurred.
Conclusion: Romiplostim was effective and well tolerated in patients with newly diagnosed, persistent, or chronic ITP in routine clinical practice.
இந்தக் கட்டுரையைப் பகிரவும்
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 